Moleculin Launches CEO Corner Platform to Share Strategic Insights
Rhea-AI Summary
Moleculin (Nasdaq: MBRX) launched CEO Corner on Feb. 13, 2026, a new video and engagement platform featuring CEO Walter Klemp.
The platform aims to provide investors with added perspective on corporate developments, clinical trial progress and strategic initiatives, and accepts questions and topic submissions for future segments.
Positive
- None.
Negative
- None.
Market Reality Check
Peers on Argus
MBRX was modestly up 0.86% with low volume while peers showed mixed moves: LPTX up 238.84%, MBIO up 5.78%, KZIA slightly positive, and INTS/SNGX down. Momentum data only flagged ERNA moving down, reinforcing that today’s action appears stock-specific rather than a coordinated biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-02-05 | Investor webinar update | Neutral | -6.5% | Announcement of participation in Webull Corporate Connect webinar series. |
| 2026-01-15 | Operational expansion | Positive | +3.1% | U.S. fulfillment hub established via third‑party logistics agreement. |
| 2026-01-13 | Safety data update | Positive | +5.9% | Independent assessment found no cardiotoxicity for Annamycin in 90 subjects. |
| 2026-01-12 | Clinical roadmap | Positive | +1.8% | Outlined 2026–2028 milestones for Annamycin and WP1066, including pivotal trial plans. |
| 2025-12-17 | Phase 1 trial results | Positive | -11.7% | Positive Phase 1 WP1066 data in pediatric recurrent malignant brain tumors. |
News tied to clinical progress has often seen aligned positive reactions, while even strong clinical headlines have occasionally coincided with notable sell-offs, indicating inconsistent post-news trading behavior.
Recent news for Moleculin has focused on clinical progress and investor communications. On Jan 12–13, 2026, the company highlighted accelerated 2026–2028 milestones and independent confirmation of no cardiotoxicity in 90 subjects on Annamycin, both with positive price reactions. A positive Phase 1 WP1066 pediatric brain tumor update on Dec 17, 2025 saw a sharp decline of 11.73%, underscoring volatile reactions even to favorable data. The new CEO Corner fits into this theme of expanded investor outreach and disclosure.
Regulatory & Risk Context
The company has an active S-3 shelf registration dated 2025-09-19 that remains in effect through 2028-09-19. The filing is not yet effective and there is no recorded usage, so no takedowns have been disclosed under this shelf in the provided data.
Market Pulse Summary
This announcement introduces a CEO Corner platform aimed at giving investors deeper context on corporate developments, clinical progress, and strategy. It complements recent efforts such as new investor presentations and detailed clinical updates on Annamycin and WP1066. With MBRX trading below its $12.14 200‑day MA and well under the $91.2475 52‑week high, investors may focus on how effectively this channel clarifies trial milestones, regulatory steps, and capital-planning signals, including any future use of the existing S-3 shelf.
Key Terms
clinical trial medical
AI-generated analysis. Not financial advice.
CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress
Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos
Access the Moleculin CEO Corner here
HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company’s corporate developments, clinical progress and strategic initiatives.
“Transparency and timely communication are central to building trust with our investors,” commented Klemp. “Our CEO Corner gives us the opportunity to go beyond standard press releases, providing deeper context on our pipeline programs, clinical milestones and business strategy. We are focused on advancing our lead programs, including our ongoing clinical trials, and delivering long-term value for our shareholders.”
Access the CEO Corner on the Company’s website here.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) and, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding the continued recruitment, treatment, and receipt of the unblinded data for the first 45 subjects of the MIRACLE clinical trial as described. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
FAQ
What is Moleculin's CEO Corner launched on Feb. 13, 2026 (MBRX)?
How can investors submit questions to Moleculin's CEO Corner (MBRX)?
What topics will Moleculin cover in CEO Corner videos (MBRX)?
Who hosts Moleculin's CEO Corner and why does the company say it launched it (MBRX)?
Where can investors access Moleculin's CEO Corner videos and updates (MBRX)?
